- Conditions
- HIV Infections
- Interventions
- rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Biological
- Lead sponsor
- United Biomedical
- Industry
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- San Francisco, California